LysoPC(18:0)
|
Basic information |
| Metabolite name | LysoPC(18:0) |
 | N/A |
 |
C04230 |
 |
N/A |
| Synonyms | lysoPC18:0; |
| No. of studies | 20 |
|
Basic information |
| Metabolite name | LysoPC(18:0) |
| N/A |
|
C04230 |
|
N/A |
| Synonyms | lysoPC18:0; |
| No. of studies | 20 |
|
Relationship between LysoPC(18:0) and depression (count: 20) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M029 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Up |
| Study M029 | Type2 | CUMS + BHD group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M048 | Type1 | CVS group vs. control group | Serum | Wistar rat | Down |
| Study M048 | Type2 | CVS + CSGS group vs. CVS group | Serum | Wistar rat | Up |
| Study M048 | Type2 | CVS + fluoxetine group vs. CVS group | Serum | Wistar rat | Up |
| Study M095 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M1072 | Type1 | CUMS group vs. control group | Faece | Cynomolgus monkey | Down |
| Study M1086 | Type1 | CUMS group vs. control group | Liver | C57BL/6 mouse | Up |
| Study M1117 | Type1 | MDD group vs. control group, Chinese cohort | Plasma | Human | Up |
| Study M1117 | Type1 | MDD group vs. control group, Russian cohort | Plasma | Human | Down |
| Study M122 | Type3 | paroxetine group vs. control group | Prefrontal cortex | BALB/c mouse | Up |
| Study M122 | Type3 | maprotiline group vs. control group | Prefrontal cortex | BALB/c mouse | Up |
| Study M123 | Type3 | rTMS group vs. control group | Prefrontal cortex | Wistar rat | Up |
| Study M123 | Type3 | rTMS group vs. control group | Striatum | Wistar rat | Down |
| Study M457 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M532 | Type1 | MDD group vs. control group | Plasma | Human | Up |
| Study M540 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M582 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6N mouse | Down |
| Study M582 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | C57BL/6N mouse | Up |
| Study M582 | Type3 | control + fluoxetine group vs. control group | Hippocampus | C57BL/6N mouse | Up |
| Study M681 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M681 | Type2 | CUMS + Chaihu Shu Gan San group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M690 | Type2 | CUMS + high dose of Zhi-zi-chi decoction group vs. CUMS group | Serum | Balb/c mouse | Up |
| Study M712 | Type1 | depression group vs. control group | Faece | Cynomolgus monkey | Down |
| Study M880 | Type1 | depression group vs. control group | Plasma | Cynomolgus monkey | Down |
| Study M890 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M907 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M948 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M955 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6J mouse | Down |
| Study M955 | Type2 | CUMS + deoiled sunflower seeds group vs. CUMS group | Hippocampus | C57BL/6J mouse | Up |
| Study M955 | Type2 | CUMS + deoiled and dechlorogenic acid-enriched sunflower seeds group vs. CUMS group | Hippocampus | C57BL/6J mouse | Up |